Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deborah Thomas

Showing results (131-140 of 155) with videos related to

Pageof 16
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemiaFrancis Giles, Srdan Verstovsek, Deborah Thomas, et al.
Blood|January 10, 2016
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtypeNitin Jain, Audrey V Lamb, Susan O'Brien, et al.
British Journal of Haematology|April 3, 2004
Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosomeMaha M T El-Zimaity, Hagop Kantarjian, Moshe Talpaz, et al.
Clinical Lymphoma & Myeloma|September 1, 2009
Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimensJennifer L Kelly, Stephen R Toothaker, Lauren Ciminello, et al.
The Lancet. Oncology|February 24, 2012
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 studyHagop Kantarjian, Deborah Thomas, Jeffrey Jorgensen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Multivariable model for time to first treatment in patients with chronic lymphocytic leukemiaWilliam G Wierda, Susan O'Brien, Xuemei Wang, et al.
American Journal of Hematology|January 5, 2017
Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remissionNaveen Pemmaraju, Hagop Kantarjian, Jeffrey L Jorgensen, et al.
Blood|April 13, 2006
Lenalidomide therapy in myelofibrosis with myeloid metaplasiaAyalew Tefferi, Jorge Cortes, Srdan Verstovsek, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 20, 2014
The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantationYi Zhou, Rebecca Slack, Jeffrey L Jorgensen, et al.
Cancer Biology & Therapy|July 13, 2012
Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironmentOlga Frolova, Ismael Samudio, Juliana Maria Benito, et al.
Pageof 16

Showing results (131-140 of 155) with videos related to

Sort By:
Pageof 16
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemiaFrancis Giles, Srdan Verstovsek, Deborah Thomas, et al.
Blood|January 10, 2016
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtypeNitin Jain, Audrey V Lamb, Susan O'Brien, et al.
British Journal of Haematology|April 3, 2004
Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosomeMaha M T El-Zimaity, Hagop Kantarjian, Moshe Talpaz, et al.
Clinical Lymphoma & Myeloma|September 1, 2009
Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimensJennifer L Kelly, Stephen R Toothaker, Lauren Ciminello, et al.
The Lancet. Oncology|February 24, 2012
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 studyHagop Kantarjian, Deborah Thomas, Jeffrey Jorgensen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Multivariable model for time to first treatment in patients with chronic lymphocytic leukemiaWilliam G Wierda, Susan O'Brien, Xuemei Wang, et al.
American Journal of Hematology|January 5, 2017
Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remissionNaveen Pemmaraju, Hagop Kantarjian, Jeffrey L Jorgensen, et al.
Blood|April 13, 2006
Lenalidomide therapy in myelofibrosis with myeloid metaplasiaAyalew Tefferi, Jorge Cortes, Srdan Verstovsek, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 20, 2014
The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantationYi Zhou, Rebecca Slack, Jeffrey L Jorgensen, et al.
Cancer Biology & Therapy|July 13, 2012
Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironmentOlga Frolova, Ismael Samudio, Juliana Maria Benito, et al.
Pageof 16